Insider · CIK 0002007090
Ambaw Bellete
Files at CGON (CG Oncology, Inc.). First filing -, latest -.
Ambaw Bellete files SEC Form 4 as COO and president at CGON (CG Oncology, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ambaw Bellete has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | CGON CG Oncology, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +107,508 | $0.00 | $0 | 107,508 | Apr 16, 2026 |
| Apr 15, 2025 | CGON CG Oncology, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +284,816 | $0.00 | $0 | 284,816 | Apr 16, 2025 |
Questions about Ambaw Bellete
Answered from the filings on this page, as of the latest one.
Is Ambaw Bellete buying or selling?
Ambaw Bellete has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ambaw Bellete's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ambaw Bellete has 0.
Where does Ambaw Bellete file Form 4?
Ambaw Bellete has filed Form 4 at CGON (CG Oncology, Inc.) as President and COO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.